Navigation Links
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:7/29/2013

WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

The FDA grants priority review status for a "drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness" over current therapies[1].  Currently, there is no approved treatment for Non-24 and tasimelteon has the potential to address this unmet medical need.

"We are extremely pleased that the FDA has granted tasimelteon priority review for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos M.D., Vanda's President and Chief Executive Officer.  "The agency's acceptance of the NDA and decision to place tasimelteon in a category of expedited review are important milestones for Vanda as we take another step toward our goal of providing patients with a treatment for Non-24."

The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-V), to be January 31, 2014.  The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.

About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle.  Non-24 affects a majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S.  Non-24 occurs almost entirely in individuals who lack the light sensitivity ne
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
6. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
8. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
9. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
10. EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
11. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 23 Reportlinker.com announces that a new market research ... Eli Lilly & Co.: PharmaVitae Profile ... analysis examines the historical and forecast performance for Eli ... global company strategy, portfolio and pipeline analysis and assessment ...
... Sept. 23 As technologies for fat removal become ... not only reshaping the body but also recycling the ... to the most recent statistics from the American Society ... are among the two most popular invasive and non-invasive ...
Cached Medicine Technology:Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 2Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 3Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 4Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 5Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 6Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... More than 60 new GranuFlo ... the past month to a federal multidistrict litigation ... caused by the dialysis concentrate, Bernstein Liebhard LLP ... 15th shows 2,089 cases filed in a federal ... of Massachusetts. These claims were filed on behalf ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ ... resolve,” said Steve Young of Ew Publishing; “I’ve had ... that is more intense.” , “It should be a ... migraines, that medical research is pointing to some relief ... , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found ...
(Date:9/21/2014)... Developers and plugin specialist of Final ... transition plugin entitled Transpack Vol. 3 from Pixel Film ... that will add a level of professionalism to any ... Film Studios. “Blurring the line between professional and armature, ... Transpack Vol. 3 returns with over 85 all new ...
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4
... to a report published in the October issue of ... , a grant-funded program tailored to provide advanced minimally ... helping address shortages of minority faculty members at US ... Diverse Surgeons Initiative (DSI) has helped 86 percent of ...
... Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) ... Radiology Imaging Network (ACRIN) and European Society of Breast ... study in the November issue of the Journal of ... BCSC is a collaborative effort to improve breast cancer ...
... Oct. 30 (HealthDay News) -- Hepatitis C patients who receive ... recurrent hepatitis than those who receive a liver from a ... for black patients who receive a liver from a white ... Hospital in Detroit looked at 165 hepatitis C patients who ...
... Kan. A little self-awareness can help people struggling ... professor of communication studies at the University of Kansas. ... flirting among dating adults, surveying more than 5,100 people ... "Knowing something about the way you communicate attraction says ...
... , SUNDAY, Oct. 31 (HealthDay News) -- Heat ... cool environments, a new study has found. University ... underwent a 10-day heat acclimation program achieved increases of ... and cool conditions. In terms of competitive cycling, this ...
... Reporter , FRIDAY, Oct. 29 -- A good marriage ... life and experience less pain, a new study suggests. ... that seems to buffer a patient,s emotional health," said ... the Johns Hopkins University School of Medicine in Baltimore. ...
Cached Medicine News:Health News:Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery 2Health News:Majority of community facilities performing breast MRI exams meet ACRIN and EUSOBI technical requirements 2Health News:Self awareness can help people navigate rocky seas of relationships 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: